Innovations-Investment, Processes, and Outcomes_Kureshy_5.11.11Presentation Transcript
Child Survival and Health Grants Program: INGO led Innovation and Operations Research (2008 – 2011) Nazo Kureshy, Team Leader, CSHGP Office of Health, Infectious Diseases and Nutrition Bureau for Global Health USAID
2008: CSHGP’s niche in Bureau for Global Health; Explicitly link CSHGP contributions to Bureau for Global Health’s mandate for Innovation and research; Leverage PVO entrepreneurship and creativity more explicitly
2010/11: Key principle in GHI; Grand Challenges and a growing community of innovators in USAID; BEST country actions plans/ Mission interest and engagement for innovation/OR)
FY2011 RFA : Guidance strengthens and aligns the program’s primary focus (since FY08) on innovation and operations research with USAID’s broader strategies for supporting innovation and research through a set of grand challenges to advance transformational development
Committed to fostering cross-learning and coordination among USAID’s growing community of innovators
Mission interest in and funding for expanding CSGHP innovations (Nepal, Liberia)
CSHGP’s CURRENT PORTFOLIO OF INONVATION & OPERATIONS RESEARCH
Summarized in brief: “Testing innovations to improve and scale up high impact MNCH interventions in vulnerable communities: USAID’s partnership with 14 INGOs through the CSHGP in 16 countries
Reported in 3 Congressional Reports focusing on updates to USAID’s Research Strategy – 4 th currently in progress
INNOVATION & EVIDENCE: NUTS & BOLTS
Deliberate Flexibility in Design of Innovation
PVO/local and national stakeholder driven designs responsive to local challenges
Relevance beyond project area (national policy/program; global)
Illustrative areas for innovation and OR – no themes
Developed in collaboration with BGH technical teams to link CSHGP innovations to research and incorporate GCD challenge areas, as feasible
Integrated into an effective community oriented project platform (single or multi-district)
Focus on Evide nce & Use
Credible evidence (global/national/local), new partnerships for research, relevance/use through stakeholder engagement
Innovation is defined as an approach or practice that introduces novel ways of addressing critical operational barriers to delivering (for improving the delivery and use of) high impact MNCH interventions to (in) vulnerable populations and strengthening health systems, ultimately leading to increased scale of these interventions and improved health outcomes.
Innovations require challenging existing paradigms in order to address an identified need (by key stakeholders) at national and global levels.
The proposed innovation should be an appropriate solution to a relevant public health challenge. It may include the following:
Introduction of a new approach or practice;
Substantial transformation of an existing approach or practice; and/or
Deleted: Adaptation of a successful approach or practice for a different context.
FY 2011 RFA ADDITIONAL NOTES ADDED TO DEFINITION
Clearly differentiated from existing alternatives
Incremental solutions – not innovative proposed as project strategy rather than innovative solution
May integrate innovative approaches with low-cost products and technologies, as relevant and feasible (integrated innovations)
ANATOMY OF CSHGP’s EVALUATION CRITERIA FOR INNOVATION (2008-2011) 2008 2009 2010 2011 28 points 30 points 36 points 35 points *Rationale and capacity to address key barriers *Focused description /rationale for innovation * Contribution to evidence base/furthering policy/scale up *Problem/relationship to national context *Prior research * Appropriate solution *Problem/relevance/prior research * Unconventional * Potential for Impact, sustainability, scalability *Methodology to evaluate innovation *Mechanisms to share evidence *Proposed OR design, including research questions *OR partner/demonstrated capacity * OR objectives, questions, and other design components * OR questions only * Stakeholder engagement in research and use of information (USAID Mission)
Innovation/Evidence Building Niche?
Can frame with technical interventions and/or cross-cutting approaches lenses
Proof of concept (4) + refinement/evidence building for scale up (13); of 13, 6 have some new components within innovation model
Not a specific grand challenge but sets of relevant challenges for operationalizing a range of components in a community health system (delivery to utilization/participation) relevant to national/local policy and program context
Clustering in challenge areas, particularly relevant to community level inputs and packaging
Technology and mHealth
Developing new or improving community platforms for delivery and use (CHWs; community mobilization; behavior change; governance)
New practices in integration (within and outside of health)/Smart integration
New or low coverage interventions (CCM, community newborn care)
IDEAS ACROSS USAID INNOVATION MECHANISMS CSHGP Development Innovation Ventures (DIV) Grand Challenge: Saving Lives at Birth New teaming at community level for CCM Range of Task Shifting/Performance/Motivation Maternity Waiting Homes MHealth (Dimagi comm care app) Care Group model People’s Institute Model Simplified HFP-ENA model EONC network Inventory credit (bankers and farmers) E-bike Test for pre-eclampsia Mobile phones (Dimagi comm care app for maternal health; election fraud; mobile diagnosis) TBD
Flexibility vs. Themes
Thematic Challenges for strengthening a cross-country learning potential (global vs. national)
Range: strengthening coordination and collaboration across community of innovators:
Integration of technology/other new comonents with cross-cutting approaches and community systems models
Energize range of ideas? Cross-learning?
Focus on credible evidence (national/global): sufficient process learning? Creativity with new methodologies? Culture of success and failure?
Integration of innovation within NGO project ($1.75, 4-5 years) – constraining? Cleaner division between smaller proof of concepts (with greater risk) and scale up?
Ideation vs. Sale: Novelty in Innovation/Risk vs. Evidence for scaling up promising/”safer” approaches and models
Priority countries or broader? Generalizeable vs. context specific solutions? Global vs. national?